ASCO 2010

 
 
 

46th Annual Meeting of the American Society of Clinical Oncology.

 

VMPT emerges as new standard for older MM patients

Mark Fuerst Read Article
Published: 07/06/10

Multiple myeloma cells
Multiple myeloma cells

The Italian Multiple Myeloma Network, GIMEMA, has confirmed that a 4-drug combination followed by maintenance is superior to the current best standard therapy—bortezomib-melphalan-prednisone (VMP)—for elderly patients with multiple myeloma (MM). The addition of thalidomide to VMP “dramatically increased the response rate,” according to Antonio Palumbo, MD, of the University of Torino in Italy, from 24% with VMP to 38% with VMPT. He presented the phase 3 results at the annual meeting of the American Society for Clinical Oncology held recently in Chicago. [Read Article]

Chemo or ASCT for younger MM patients?

Mark Fuerst Read Article
Published: 07/03/10

 Bone marrow aspirate showing multiple myeloma
Bone marrow aspirate showing
multiple myeloma

Novel agents call into question the role of autologous stem cell transplant (ASCT) upfront for younger multiple myeloma (MM) patients. Antonio Palumbo, MD, of the University of Torino in Italy, shed some light on the question at the annual meeting of ASCO held recently. He reported the results of a phase 3 trial in newly diagnosed myeloma patients. Researchers found that 3-drug conventional chemotherapy is comparable to ASCT without the risk, recovery time, and debilitating side effects of a transplant. [Read Article]

Panobinostat-bortezomib combination promising in refractory MM

Mark Fuerst Read Article
Published: 07/02/10

Multiple myeloma cells
Multiple myeloma cells

Panobinostat (LBH589) combined with bortezomib shows promising activity in patients with relapsed or relapsed/refractory multiple myeloma (MM). Even patients refractory to prior bortezomib-containing regimens benefitted from the combination. Kenneth Anderson, MD, of the Dana-Farber Cancer Institute in Boston, reported the phase 1 results at the annual meeting of the American Society of Clinical Oncology held recently in Chicago. [Read Article]

Lenalidomide maintenance reduces recurrence in MM

Alice Goodman Read Article
Published: 07/01/10

Multiple myeloma cells
Multiple myeloma cells

Lenalidomide maintenance therapy halved the recurrence rate in patients with multiple myeloma (MM) following first-line autologous stem cell transplant (ASCT) in a 24-month interim analsyis of a phase 3 study presented at an oral session of the 2010 Annual Meeting of ASCO, held here. “This 24-month interim analysis suggests that lenalidomide may be the first effective maintenance therapy for MM,” said lead investigator Michel Attal, MD, of Purpan Hospital in Toulouse, France, speaking for the Intergroupe Francophone du Myélome. [Read Article]

Bosutinib in imatinib-resistant/intolerant chronic CML

Alice Goodman Read Article
Published: 06/30/10

CML cells
CML cells

The investigational tyrosine kinase inhibitor bosutinib was effective in patients with chronic-phase chronic myelogenous leukemia (CML) who failed on previous therapy with imatinib—current first-line therapy for this hematologic cancer. Half of the patients who were either imatinib-resistant or imatinib-intolerant achieved a complete cytogenetic response (CCyR) with bosutinib, according to a study presented at the 2010 annual meeting of ASCO. A second study showed that bosutinib was also effective as third-line therapy in chronic phase CML, after failure on imatinib and second-line dasatinib. [Read Article]

Smoking increases risk of fungal disease in AML

Alice Goodman Read Article
Published: 06/28/10

A study presented at ASCO 2010 suggests that patients with acute myeloid leukemia (AML) who smoke cigarettes are at increased risk for invasive fungal disease and should therefore be given intensive antifungal prophylaxis before undergoing induction chemotherapy. “This finding is important but not well known. Oncologists should be aware of the need for prophylaxis in AML patients who smoke cigarettes and are about to go undergo induction chemotherapy,” said lead author Mary G. Mansour, MD, from the Cleveland Clinic Taussig Cancer Institute in Ohio. [Read Article]

Rituximab beneficial for maintenance, not purging in FL

Alice Goodman Read Article
Published: 06/25/10

Follicular lymphoma cells
Follicular lymphoma cells

The European Group for Blood and Marrow Transplantation (EBMT)-LYM-1 study showed that purging for stem cell harvest with rituximab was of no benefit, but that rituximab maintenance therapy improved progression-free survival (PFS) in rituximab-naïve patients with follicular lymphoma (FL) undergoing stem cell transplantation. Experts said this study does not address whether these results would be similar in patients with follicular lymphoma treated up front with rituximab. [Read Article]

Encouraging results for SCT in myelofibrosis

Alice Goodman Read Article
Published: 06/24/10

Stem cells
Stem cells

An interim analysis of the first prospective study of fludarabine-based reduced intensity conditioning for allogeneic stem cell transplantation (ASCT) for patients with myelofibrosis confirms that transplantation can now be considered a treatment for this disorder, which until now did not have any good treatment. “Ours is the first study of this type of transplant in the US. There has been one in Europe as well. I think these results will consolidate that transplant should be offered to all patients with myelofibrosis and a related donor,” said Damiano Rondelli, MD, of University of Illinois in Chicago. [Read Article]

High IL-6, increased mortality in elderly CML

Alice Goodman Read Article
Published: 06/23/10

 Peripheral blood smear showing CLL
Peripheral blood smear
showing CLL

High serum levels of interleukin-6 (IL-6) in patients with chronic lymphocytic leukemia (CLL) were associated with a significantly increased risk of mortality, particularly in older patients, in a prospective study reported at the 2010 Annual Meeting of ASCO, held in Chicago. Cardiovascular disease, although not the primary cause of death in CLL patients, was also associated with high IL-6 levels, and the authors of this study believe that high levels of IL-6 may contribute to CLL progression. [Read Article]

Single-agent panobinostat shows promise in relapsed/refractory HL

Mark Fuerst Read Article
Published: 06/16/10

Hodgkin’s lymphoma cells
Hodgkin’s lymphoma cells

The largest prospective trial ever conducted in post-transplant relapsed/refractory Hodgkin’s lymphoma shows that the histone deacetylase inhibitor panobinostat as a single agent induces promising activity and durable responses. Although first-line conventional chemo-radiotherapy cures a vast majority of Hodgkin’s lymphoma patients, and autologous hematopoietic stem cell transplantation (AHSCT) is the standard therapy for relapsing patients, a high percentage of patients relapse after transplantation and have a poor long-term outcome, said Anna Sureda, MD, PhD, from Hospital de la Santa Creu in Barcelona at the 2010 ASCO meeting. [Read Article]

Second generation TKIs may surpass imatinib as frontline therapy for CML

Mark Fuerst Read Article
Published: 06/11/10

CML cells
CML cells

Two head-to-head long-term studies show two second-generation tyrosine kinase inhibitors (TKIs) may be superior to imatinib in the front-line treatment of newly diagnosed Philadelphia-positive chronic myeloid leukemia (CML). But some clinicians may prefer to wait for survival data before switching away from gold-standard imatinib therapy.Two new pivotal phase 3 clinical trials show nilotinib and dasatinib are on the verge of challenging imatinib as the drug of choice for newly diagnosed chronic CML, according to presentations at the American Society of Clinical Oncology annual meeting held June 4-8 in Chicago. [Read Article]

Zoledronic acid improves survival in MM patients

Mark Fuerst Read Article
Published: 06/10/10

Multiple myeloma cells
Multiple myeloma cells

Adding the bisphosphonate zoledronic acid to first-line chemotherapy significantly improves survival for newly diagnosed multiple myeloma (MM) patients, according to the results of a large phase 3 trial. “Zoledronic acid is superior to clodronate for the prevention of SREs in patients with newly diagnosed MM and prolongs overall survival versus clodronate,” said Dr Gareth Morgan of Royal Marsden Hospital, London [Read Article]

    {title}

    {icon} {author} Read Article
    Published: {pubDate}

    {summary}